Acorda Therapeutics Inc (ACOR)

21.80
0.25 1.16
NASDAQ : Health Care
Prev Close 21.55
Open 21.40
Day Low/High 21.00 / 22.35
52 Wk Low/High 23.85 / 43.63
Volume 681.14K
Avg Volume 819.80K
Exchange NASDAQ
Shares Outstanding 46.65M
Market Cap 988.99M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

September 15th Options Now Available For Acorda Therapeutics (ACOR)

Investors in Acorda Therapeutics Inc saw new options begin trading today, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new September 15th contracts and identified one put and one call contract of particular interest.

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

Short Interest Makes 16% Move For ACOR

Short Interest Makes 16% Move For ACOR

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 1,046,512 share increase in total short interest for Acorda Therapeutics Inc , to 7,545,998, an increase of 16.10% since 06/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Acorda Second Quarter 2017 Update Webcast/Conference Call Scheduled For July 27, 2017

Acorda Second Quarter 2017 Update Webcast/Conference Call Scheduled For July 27, 2017

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to review its second quarter 2017 financial results and pipeline updates on Thursday, July 27 at 8:30 a.

Acorda Submits New Drug Application To U.S. Food And Drug Administration For INBRIJATM (CVT-301, Levodopa Inhalation Powder)

Acorda Submits New Drug Application To U.S. Food And Drug Administration For INBRIJATM (CVT-301, Levodopa Inhalation Powder)

Acorda Therapeutics, Inc. (NASDAQ: ACOR) has submitted a New Drug Application (NDA) to the U.

Biotech Insider Just Loaded Up $234 Million Worth the Stock

Biotech Insider Just Loaded Up $234 Million Worth the Stock

Massive biotech bet!

Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe

Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe

Adamis Pharmaceuticals, Impax Laboratories and Accorda Therapeutics were among the biotech stock movers in premarket trading on June 16.

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Albany Molecular Research, Acorda Therapeutics and PTC Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Acorda Presenting New Tozadenant Data At 2017 MDS Congress

Acorda Therapeutics, Inc. (Nasdaq: ACOR) is presenting new data from clinical and preclinical studies of tozadenant at the 2017 International Congress of Parkinson's Disease and Movement Disorders (MDS), being held in...

CVT-301 Phase 3 Data Showed Significantly Improved Motor Function During OFF Periods In Parkinson's Disease

Acorda Therapeutics, Inc. (Nasdaq: ACOR) presented data from its Phase 3 SPAN-PD clinical trial of CVT-301 (levodopa inhalation powder) that showed a statistically significant, clinically meaningful improvement in motor...

Acorda To Present At The Goldman Sachs Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present at the Goldman Sachs Global Healthcare Conference on Wednesday, June 14, 2017 at 8:40 a.

Oversold Conditions For Acorda Therapeutics (ACOR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Acorda To Present New INBRIJA™ (Levodopa Inhalation Powder) Phase 3 Data At Upcoming MDS Congress

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present new data from the Phase 3 clinical trial of INBRIJA TM (levodopa inhalation powder) at the International Congress of Parkinson's Disease and Movement Disorders (MDS),...

Acorda To Present At The Deutsche Bank 42nd Annual Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present at the Deutsche Bank 42nd Annual Healthcare Conference in Boston on Thursday, May 4, 2017 at 11:20 a.

Biotech Movers: Intra-Cellular Therapies, Organovo, Acorda

Biotech Movers: Intra-Cellular Therapies, Organovo, Acorda

Intra-Cellular Therapies, Organovo Holdings and Acorda Therapeutics were among the biotech stock movers in premarket trading on Monday.

Acorda Expands Alexa Skill Offering For Parkinson's Awareness Month

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the launch of The Many Faces of OFF¿ Facebook Feed, a new skill for the Amazon Alexa, as part of the company's activities in recognition of Parkinson's...

Acorda Shares Fall 5% in an Earnings Miss

Acorda Shares Fall 5% in an Earnings Miss

Net revenue for its Ampyra totaled $112 million, short of the $121 million consensus.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Acorda Provides Financial And Pipeline Update For First Quarter 2017

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced financial results for its first quarter ended March 31, 2017, and provided an update on the Company's pipeline, financial guidance and corporate restructuring.

Commit To Purchase Acorda Therapeutics At $13, Earn 14.2% Annualized Using Options

Investors considering a purchase of Acorda Therapeutics Inc shares, but tentative about paying the going market price of $16.35/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $13 strike, which has a bid at the time of this writing of 90 cents.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAN, CR, CVLT, CWCO, GPRK, KMB, MDLZ, MVC, OPB, POL, PW, RMBS, SNY Downgrades: ACOR, AKR, FCCY, NRZ, QGEN, SSY, SWFT, TBBK, WRI Initiations: UA Read on to get TheStreet Quant Ratings' detailed report:

Acorda To Host Conference Call To Discuss First Quarter 2017 On April 27, 2017

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its first quarter 2017 financial results and pipeline updates on Thursday, April 27 at 8:30 a.

Acorda CEO Risks All, Loses Nothing, When Drug Patent Strategy Backfires, Employees Fired

Acorda CEO Risks All, Loses Nothing, When Drug Patent Strategy Backfires, Employees Fired

Biotech is an inherently risky business, so layoffs are an unfortunate consequence of bad things happening. But Acorda's situation is a different because the company was extra risky from founding.

Acorda Therapeutics Implements Corporate Restructuring To Align Cost Structure With Focus On Promising Late-Stage Programs

Acorda Therapeutics, Inc. (Nasdaq:  ACOR) today announced a corporate restructuring to reduce its cost structure and focus its resources on its two late-stage programs, CVT-301 and tozadenant, as well as on maximizing...

Acorda Shares Fall 21% on Patent Ruling Loss That Clears Way for MS Generic

Acorda Shares Fall 21% on Patent Ruling Loss That Clears Way for MS Generic

A District Court judge found four Acorda patents on Ampyra were invalid due to obviousness.

U.S. District Court Issues Decision To Invalidate Four AMPYRA Patents; Company Will Appeal Ruling

Acorda Therapeutics, Inc. (Nasdaq:  ACOR ) today announced that the United States District Court for the District of Delaware upheld U.